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Bullous pemphigoid is a blistering disorder associ-
ated with autoantibodies directed against two
components of hemidesmosomes, BP180 and BP230.
Autoantibodies to the extracellular collagenous
domain of BP180 are thought to play a key role in
the pathogenesis of the disease. In a murine model
of bullous pemphigoid, neutrophil elastase and
92 kDa gelatinase (matrix metalloproteinase 9) have
been implicated in subepidermal blister formation
via proteolytic degradation of BP180. In this study
we sought to elucidate the contribution of these two
enzymes to subepidermal blister formation by assess-
ing the expression, localization, and activity of the
two proteases in lesional skin, serum samples, and
blister ¯uids obtained from 17 patients with bullous
pemphigoid. The results indicate that (i) neutrophil
elastase is found in skin biopsy specimens from
bullous pemphigoid lesions and is recovered as active
enzyme in blister ¯uids, and (ii) although proform of
matrix metalloproteinase 9 is present in lesional skin,
it is present only as proenzyme in blister ¯uids,
which also contain high levels of tissue inhibitor of
metalloproteinase-1. Next, the capacity of matrix
metalloproteinase 9 and neutrophil elastase to
degrade a recombinant protein corresponding to the
extracellular collagenous domain of the BP180 was
studied. Our data illustrate that (i) recombinant mat-
rix metalloproteinase 9, neutrophil elastase, and blis-
ter ¯uid from bullous pemphigoid patients are all
able to hydrolyze recombinant BP180; (ii) the
pattern of recombinant BP180 proteolysis with
blister ¯uid was similar to that obtained with neutro-
phil elastase; and (iii) recombinant BP180 degrad-
ation by blister ¯uid could be inhibited by
chloromethylketone, a speci®c elastase inhibitor, but
not by batimastat, a wide spectrum matrix metallo-
proteinase inhibitor. Our results con®rm the import-
ance of neutrophil elastase but not matrix
metalloproteinase 9 in the direct cleavage of BP180
autoantigen and subepidermal blister formation in
human bullous pemphigoid. Key words: bullous pem-
phigoid/matrix metalloproteinase/neutrophil elastase. J
Invest Dermatol 117:1091±1096, 2001
B
ullous pemphigoid (BP) is an autoimmune disease
characterized by subepidermal blisters associated with
autoantibodies directed against two components of
adhesion complexes called hemidesmosomes, BP180
and BP230 (Stanley et al, 1984; Labib et al, 1986;
Giudice et al, 1993; Zillikens et al, 1997). BP180, also known as
type XVII collagen, is a transmembrane protein whereas BP230 is a
cytoplasmic protein of the plakin protein family involved in the
attachment of the keratin ®laments to the plasma membrane
(Borradori and Sonnenberg, 1999). BP180 is the main antigenic
target of BP autoantibodies (Labib et al, 1986; Giudice et al, 1992;
Zillikens et al, 1997). BP antibodies have been shown to
predominantly react with antigenic sites clustered within a
noncollagenous BP180 region adjacent to the membrane spanning
domain, the NC16A domain (Giudice et al, 1993; Matsumura et al,
1996; Zillikens et al, 1997).
Recently, it has been shown that a protease-mediated shedding
of the extracellular domain of BP180 from human keratinocytes
occurs under physiologic conditions. It consists in the release by the
cells of a 120 kDa proteolytic extracellular fragment (Hirako et al,
1998; SchaÈcke et al, 1998). The contribution of neutral proteinases
in BP180 shedding in blistering diseases has been emphasized
previously (Stahle-BaÈckdahl et al, 1994).
In an experimental model of BP in mice, anti-BP180
autoantibodies trigger subepidermal blister formation via comple-
ment activation, recruitment of neutrophils, and liberation of
proteases. Among these enzymes, 92 kDa gelatinase (matrix
metalloproteinase 9, MMP-9) and neutrophil elastase (NE) prob-
ably play a prominent role. Indeed, both MMP-9- and NE-
de®cient mice were found to be resistant to experimental BP (Liu
et al, 1995; 1998; 2000). In this mouse BP model, Liu et al (2000)
recently showed that MMP-9 acts to regulate NE activity by
inactivating a1-proteinase inhibitor, whereas NE is the major
tissue-damaging enzyme that produces BP180 degradation and
dermal±epidermal separation.
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Figure 1. Immunolocalization of MMP-9 and human NE in skin lesions from BP and other in¯ammatory skin disorders. Labeling of
gelatinase B (B, E, F, G, H) and human NE (C, D) on paraf®n sections of skin biopsy specimens from a BP patient (lesional skin, i.e., recent blister),
patients with other in¯ammatory skin disorders (eczema, lichen planus, psoriasis), and normal human skin using speci®c monoclonal antibodies as
described in Materials and Methods. MMP-9 and NE labeling were found in in¯ammatory cells (eosinophils and neutrophils) (A, C) but not in adjacent
keratinocytes (B, D). Positive immunostaining was found in altered keratinocytes of various in¯ammatory dermatoses: keratinocytes surrounded with
spongiosis in eczema (E), necrotic basal keratinocytes in lichen planus (F), and keratinocytes in a several-days-old BP blister (H). Normal keratinocytes
from psoriatic epidermis (G) or a fresh BP blister (B) did not show MMP-9 labeling.
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In contrast to this elegant BP murine model, only few studies
(Stahle-BaÈckdahl et al, 1994) have been devoted to the respective
contributions of these two proteases, i.e., MMP-9 and NE in vivo in
human BP. In vivo, the activity of those proteases is controlled by
speci®c inhibitors with molar concentrations that generally exceed
enzyme levels (Basbaum and Werb, 1996).
In order to gain further insight into the pathophysiology of BP,
levels of MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1),
and active NE were determined in blister ¯uids from patients.
Furthermore, the ability of both puri®ed enzymes and blister ¯uids
from BP patients to degrade a recombinant form of the extracellular
domain of BP180 was assessed. Finally the expression of MMP-9
and NE in diseased skin was assessed by immunohistochemistry.
Our ®ndings suggest that in human BP NE probably acts directly
on BP180 autoantigen, whereas MMP-9, present at a much lower
concentration and only as inactive zymogen, probably plays a
minor role, if any, in the dermal±epidermal cleavage.
MATERIALS AND METHODS
Patients Seventeen consecutive patients with a mean age of 73 y
(range 51±90 y) ful®lling the clinical and immunopathologic criteria of
BP were studied. Serum samples were analyzed by indirect
immuno¯uorescence microscopy studies (staining of the epidermal side
of 1 M NaCl split skin) and by immunoblotting of epidermal extract as
previously reported (Bernard et al, 1989). Circulating autoantibodies
directed against BP180 and BP230 were detected in nine and ®ve
patients, respectively, whereas in three cases no serum reactivity was
found by immunoblotting.
Blister ¯uid from six patients with a mean age of 75 y with widespread
blistering was collected using a sterile syringe, centrifuged, and stored at
±80°C until use. By immunoblotting, reactivity with BP180 and BP230
was detected in four and two, respectively, of the sera of these BP
patients.
Immunohistochemistry Paraf®n sections from lesional BP (n = 17)
and other in¯ammatory skin diseases (eczema, lichen planus, psoriasis) as
well as normal human skin biopsy specimens (n = 8) were studied.
Sections were rehydrated and treated with 0.3% hydrogen peroxide for
5 min to quench endogenous peroxidase activity. Non-speci®c binding
was blocked with phosphate-buffered saline (PBS) containing carrier
protein and 15 mM sodium azide (Dako, Carpinteria, CA) for 20 min.
Slides were incubated overnight at 4°C with anti-MMP-9 monoclonal
antibody (2 mg per ml) (Oncologix, Gaithersburg, MD) or 30 min at
room temperature with anti-NE monoclonal antibody (Dako). Negative
controls were carried out by omitting the primary antibody. After three
washes (10 min) in PBS, subsequent steps were performed using the
peroxidase LSAB kit (labelled streptavidin±biotin method, Dako)
according to the manufacturer's instructions. Peroxidase activity was
revealed with 3-amino-9-ethylcarbazole chromogen, which gives a red-
brown product. All slides were counterstained with Mayer's
haematoxylin or green ethyl (Nawrocki et al, 1997).
Measurement of human NE activity in blister ¯uid Human NE
activity was determined in blister ¯uid of BP patients (n = 6) using a
speci®c chromogenic substrate: MeOSuc-Ala-Ala-Pro-Val-paranitro-
anilide (Lestienne et al, 1980).
One nanogram or 5 ng of the active enzyme (Elastin Products
Company) (standard curve) or a de®ned blister ¯uid volume was mixed
in a 50 mM Tris-HCl buffer containing 150 mM NaCl, pH 8.0, and
assay was initiated by addition of 0.6 mM chromogenic substrate. The
rate of substrate hydrolysis by NE-containing blister ¯uid was linear from
0 to 180 min under our experimental conditions using a Titertek
Multiskan Plus spectrophotometer at 405 nm. NE activity in blister ¯uid
was expressed as ng HLE equivalent per mg protein.
Gelatin zymography Blister ¯uids were analysed in either the absence
or the presence of 1 mmol per l acetylphenylmercuric acid (APMA) for
2 h at 37°C to activate gelatinases. Zymography was performed in 0.1%
gelatin and 10% sodium dodecyl sulfate (SDS) polyacrylamide gels. After
electrophoresis, gels were washed in 2% Triton-100 at room temperature
and incubated at 37°C overnight in 50 mM Tris HCl, pH 7.6, 10 mmol
per l CaCl2, to allow renaturation of enzyme activity, without or with
ethylenediamine tetraacetic acid in order to inactivate MMP. Gels were
then stained with Coomasie blue, and gelatinase bands appeared white
on a blue background (Emonard and Hornebeck, 1997).
Enzyme-linked immunosorbent assay (ELISA) Quanti®cation of
MMP-9 and TIMP-1 in blister ¯uids (n = 6 patients) was performed
using ELISA kits from Calbiochem-Oncogene Research Products
(France Biochem, Meudon, France) according to the manufacturer's
instructions. Results were expressed as micrograms of enzyme or
inhibitor per milligram of total protein. Total protein concentration in
blister ¯uids was quanti®ed using the Lowry method (Waterborg and
Matthews, 1994).
CDNA construct and recombinant form of BP180 A eukaryotic
expression plasmid (pcDNA3, Invitrogen, San Diego, CA) encoding for
the entire extracellular domain of BP180 (residues 490±1497) including
the last four COOH terminal amino acids of its transmembrane domain
was used (Perriard et al, 1999). The recombinant form of BP180, which
contained at its NH2-terminus a c-myc epitope (MEQKLISQQDL) for
immunodetection, was produced by an in vitro transcription and
translation system (TNT T7 coupled Reticulocyte Lysate System,
Promega, Madison, WI) as reported in detail elsewhere (Skaria et al,
2000). For radioactive control reactions, an amino acid mixture minus
methionine with 40 mCi 35S methionine was used.
Degradation studies The in vitro translation product was incubated
with protease for 4 h at 37°C at a ®nal concentration of 35.8 nM MMP-
9 or 16.4 nM human NE, respectively, or with pure blister ¯uid from a
patient with severe and active BP. To study inhibition of recombinant
BP180 proteolysis by blister ¯uid, pure blister ¯uid was incubated for
30 min at 37°C with inhibitors of MMP-9 and NE, batimastat and a
speci®c peptide chloromethylketone elastase inhibitor (MeOSuc-Ala-Ala-
Pro-Val-CH2Cl), respectively, at a ®nal concentration of 1 mM. After
incubation, samples were electrophoresed on 7.5% SDS polyacylamide
gel and analyzed for BP180 proteolysis by autoradiography.
RESULTS AND DISCUSSION
Localization of proteases in BP lesions by immunohisto-
chemistry In a previous study performed on human diseased
skin of BP patients, in situ hybridization as well as immunohisto-
chemistry showed that degranulated eosinophils produce large
amounts of MMP-9, whereas the gelatinase mRNA signal was
most pronounced at the ¯oor of the forming blister where
eosinophils accumulated (Stahle-BaÈckdahl et al, 1994).
In our study, eosinophils as well as neutrophils of lesional BP skin
showed positive immunostaining with anti-MMP-9 antibody
whereas no signal was seen in sections processed without primary
antibody (data not shown). Staining was negative within the
epidermis of a recent blister (Fig 1A). Interestingly, positive
MMP-9 immunostaining was seen in necrotic or altered keratino-
cytes from several in¯ammatory skin diseases: keratinocytes
surrounded with spongiosis (Fig 1E), necrotic basal keratinocytes
from lichen planus (Fig 1F), and necrotic epidermal keratinocytes
from an old BP blister (Fig 1H). In contrast, no MMP-9
Figure 2. Human NE free enzyme activity in BP blister ¯uid of
six patients. Human NE activity was assessed in blister ¯uids of six
patients using a sensitive speci®c substrate (MeOSuc-(Ala)2-Pro-Val-p-
NA) as described in Materials and Methods. Variable NE activity was
found in all blister ¯uids ranging from 1 pg per mg (patient 3) to 65 pg
per mg (patient 2).
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immunostaining was seen in acanthotic epidermis from psoriatic
lesions (Fig 1G), in a recent BP blister (Fig 1B), or in normal
human skin. Immunostaining of sections from lesional BP skin was
also performed using NE antibody. Similarly, a strong labeling was
observed predominantly in polymorphonuclear neutrophils close to
the dermal±epidermal cleavage located within blisters (Fig 1C),
whereas no labeling was seen in keratinocytes (Fig 1D).
Presence of elastase activity in BP blister ¯uids The serine
protease NE is secreted as an active enzyme by azurophil granules
of neutrophils, the concentration of which in cells is very high
(5 mM). The proteolytic activity of this protease can be measured
using MeOSuc-(Ala)2-Pro-Val-p-NA, a speci®c chromogenic
substrate for the enzyme (Lestienne et al, 1980). The presence of
NE activity in various bullous diseases including BP has been
documented in previous studies (Oikarinen et al, 1983; 1986;
Welgus et al, 1986). In our study, blister ¯uids from all tested BP
patients (n = 6) were found to contain active enzyme, the content
of which varied from 1 to 65 pg NE per mg (mean 23 pg per mg 6
22) (Fig 2).
Quanti®cation of MMP-9 and TIMP-1 in BP blister
¯uids MMP have been implicated in the pathophysiology of
several blistering diseases such as pemphigus, dermatitis
herpetiformis, and BP (Oikarinen et al, 1983; Welgus et al,
1986). In BP, MMP-9 has been reported to be secreted in blister
¯uid as proenzyme (Oikarinen et al, 1993; Paquet et al, 1998).
In our study, the presence of gelatinases (MMP-9, MMP-2)
within blister ¯uids was ®rst examined by gelatin zymography.
Several lysis bands at 120 kDa, 92 kDa, and 72 kDa could be seen
in all samples (Fig 3). Proteolytic activity could be suppressed by
adding to the incubation buffer either ethylenediamine tetraacetic
acid (5 mM), which inhibits gelatinase activity by chelating Zn in
the catalytic site of the enzyme, or batimastat (3 mM), a speci®c
matrixin inhibitor (Yip et al, 1999) (not shown). Pretreatment with
an organomercurial agent (APMA), which activates gelatinase
through autocatalytic cleavage of the prodomain, led to the
formation of lower gelatinolytic species at 84 kDa and 64 kDa.
Consistent with previous observations (Paquet et al, 1998), BP
blister ¯uids contained only proforms of the 92 kDa MMP-9 and
the 72 kDa MMP-2. The gelatinolytic bands exhibiting lower
electrophoretic migration most probably represented dimer com-
plexes that could not be separated under the nondenaturing
conditions used for the zymogram.
Previous studies have indicated that MMP-9 and TIMP-1 are
coregulated (Buisson-Legendre et al, 2000) and are expressed in a
tissue and temporal regulated manner during disease (Vaalamo et al,
1996). TIMP-1 level has never been previously studied in BP. In
our study, ELISA was performed to assess the amounts of MMP-9
Figure 3. Presence of metalloproteinases in BP blister ¯uid by
gelatin zymography. Blister ¯uid of three BP patients was analyzed
using gelatin zymography (lanes 2, 4, 6) as described in Materials and
Methods. Proenzymes present in blister ¯uids were activated by APMA
(lanes 3, 5, 7). Lane 1 is a control of recombinant MMP-9 (92 kDa).
MMP-9 (92 kDa) and MMP-2 (72 kDa) were present in all blister ¯uids
as proenzymes and could be activated by APMA. Higher gelatinolytic
bands probably corresponded to dimer formation.
Figure 4. Level of MMP-9 and TIMP-1 in BP blister ¯uid of six
patients. Levels of MMP-9 (black column) and TIMP-1 (striped column)
were quanti®ed in blister ¯uids from six patients using ELISA. On
average, TIMP-1 concentration was 6.22-fold higher than MMP-9 level
on a molar basis.
Figure 5. In vitro degradation of a recombinant form of the
extracellular domain of BP180. 35S-labeled recombinant BP180
(100 kDa) (lane 1, control) was incubated with 33 ng (35.8 nM) of
MMP-9 (lane 2); 50 ng (62.4 nM) of MMP-9 (lane 3); 5 ng (16.9 nM)
of NE (lane 4); or pure blister ¯uid from a BP patient (lane 5).
Degradation of recombinant BP180 was observed with all tested
proteases as with BP blister ¯uid. Main 74 kDa, 45 kDa, and 31 kDa
proteolytic species were identi®ed.
Figure 6. Inhibition of the degradation of the recombinant form
of BP180 by protease inhibitors. The 35S-labelled recombinant
BP180 (100 kDa) (lane 1, control) was incubated with blister ¯uid from
a BP patient, either alone (lane 2) or with peptide chloromethylketone
elastase inhibitor (lane 3), or batimastat (lane 4). Only addition of elastase
inhibitor prevented degradation of recombinant BP180 100 kDa protein,
whereas batimastat did not.
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and TIMP-1 present in blister ¯uids from six BP patients. The
results (Fig 4) indicate that MMP-9 levels in ¯uids vary from 0.03
to 0.05 mg per mg protein, a range close to values previously
reported by Stahle-BaÈckdahl et al (1994), whereas TIMP-1
concentrations vary from 0.01 to 0.1 mg per mg protein, with an
approximately 5±10-fold molar excess of TIMP-1 over MMP-9. It
is noteworthy that both MMP-9 and TIMP-1 appeared to be more
strongly elevated in blister ¯uids obtained from the most in¯am-
matory BP lesions. In addition, the relative levels of enzyme and
inhibitors seemed to remain similar between patients, supporting
the hypothesis that both proteinase and proteinase inhibitors were
secreted by the same cell type such as polymorphonuclear cells in
BP.
In some conditions, however, such as in cutaneous repair,
MMP-9 and TIMP-1 can be produced by distinct cell types. In
fact, transcripts for TIMP-1 are found con®ned exclusively to the
dermis, whereas subpopulations of basal keratinocytes express
MMP-9 after cutaneous injury (Parks, 1999). Our data con®rm that
MMP-9 is expressed in BP lesions as inactive zymogen but add new
information about the presence in large excess at the same
localization of its speci®c inhibitor TIMP-1. Taking these data
together, we can conclude that, in human BP, MMP-9 probably
could not act on its speci®c substrate within the basement
membrane zone of the epidermis.
Degradation of recombinant BP180 by MMP and leucocyte
elastase Murine BP180 was previously reported to be susceptible
to proteolysis by MMP-9 and NE (Liu et al, 2000). Extensive
degradation of this protein, however, was obtained at enzyme
concentrations substantially greater than those found in blister ¯uid.
A small portion of human recombinant BP180 ectodomain has also
been reported to be ef®ciently degraded by 92 kDa MMP-9
(Stahle-BaÈckdahl et al, 1994). We used the entire extracellular
domain of BP180 to assess the capacity of the two proteinases
present in BP lesions (MMP-9, NE) to degrade BP180. Under our
experimental conditions, partial proteolysis was observed following
incubation of the recombinant form of BP180 with 35.8 nM of
MMP-9 or 16.9 nM NE for 4 h. For both enzymes the main
proteolytic fragment exhibited a molecular weight of
approximately 74 kDa, but degradation products of 45 kDa and
31 kDa could also be identi®ed. At a ®nal concentration of
35.8 nM, MMP-9 was able to degrade recombinant BP180
similarly to NE, whereas at a concentration of 3.5 nM MMP-9
did not demonstrate proteolytic activity on recombinant BP180. In
parallel studies, we further analyzed the capacity of NE contained in
blister ¯uid from BP patients to hydrolyze BP180 (Fig 5, lane 4).
The pattern of proteolytic digestion of the recombinant form of
BP180 obtained after incubation with blister ¯uid was similar to
that obtained with NE. The different intensities of the signals in
Fig 5 (lane 1) and Fig 6 (lane 1) are due to differences in the
radiolabelling with 35S of the recombinant BP180 fragment, as
experiments were done at a different period of time with the
radiolabeled protein although we used the same quantity of protein
in both experiments. Importantly, protein degradation could be
inhibited by a speci®c elastase inhibitor, peptide chloromethyl-
ketone (MeOSuc-Ala-Ala-Pro-Val-CH2Cl), but not by batimastat,
a wide spectrum MMP inhibitor (Fig 6, lanes 3, 4).
In vivo, BP180, as one collagen type, exhibits triple helicoidal
conformation with intervening sequences. In vitro, reconstitution of
such structure proved to be rather dif®cult to achieve and only
epidermal extracts were shown to contain trimeric complexes on
Western blot run under nonreducing conditions (Pas et al, 1999).
We ®rst attempted to investigate BP180 proteolysis by human NE
and MMP-9 using such epidermal extracts; data obtained were
inconsistent due to the presence of protease inhibitors in the
extracts. The capacity of NE and MMP-9 to degrade BP180 was
therefore on a monomeric polypeptide fragment representing the
entire extracellular part of the protein. Results obtained were
similar to those reported with another baculovirus-encoded form of
BP180 (Haase et al, 1998) (results not shown), indicating that both
NE and MMP-9 could hydrolyse this polypeptide. In blister ¯uid
from BP patients, however, human NE, but not MMP-9, was
identi®ed as an active enzyme able to degrade BP180. It suggested
that, even at distant sites, control of that enzyme by its natural
inhibitors, i.e., a1-proteinase inhibitor and ela®n, is impaired. As its
concentration in the azurophilic granules (5 mM) is several orders
of magnitude higher than any inhibitor concentration, local
proteolysis of the dermal±epidermal junction proteins by human
NE is probably uncontrolled. Furthermore, NE was shown to be
able to bind to the cell surface of neutrophils, a mechanism that
focuses and preserves catalytic activity of the enzyme.
Previous studies demonstrated that MMP-9 de®ciency in mice
did not modify neutrophil migration into the skin but inhibited
subepidermal blistering of experimental BP (Liu et al, 1995). We
here con®rmed that, in humans, this enzyme could be identi®ed
only as a proenzyme at a molar concentration lower than active NE
in BP. In addition, its natural occurring inhibitor TIMP-1 is present
in molar excess, indicating that, contrary to human NE, this
enzyme does not contribute to diffuse proteolysis. At the neutrophil
pericellular environment, activated MMP-9 could degrade a1-
proteinase inhibitor, amplifying NE proteolysis by such mechan-
ism. Binding of MMP-9 to neutrophil membrane, however, was
shown to be very weak, and only cathepsin G, among skin elastases,
was found to slowly activate membrane-associated pro-MMP-9.
Together, our data further emphasize the crucial importance of NE
in human BP; the contribution of other neutral endopeptidases,
such as MMP-9, in disease progression is not as clear in humans as it
is in mice (Liu et al, 2000). Finally, it must be emphasized that,
contrary to dogs, whose BP180 autoantigen shares 87% identity
with its human counterpart (Xu et al, 2000), mice do not develop
spontaneous BP disease.
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